Cell Pathways CP461 demonstrates multiple anti-cancer ...( HORSHAM PA (April 8 2002): Eight scie...)

HORSHAM, PA (April 8, 2002): Eight scientific posters presented by scientists from Cell Pathways, Inc. (Nasdaq: CLPA) and their collaborators at the American Association of Cancer Research (AACR) meeting in San Francisco this week further detail the anti-cancer properties and mechanism of action for the companys selective apoptotic antineoplastic drugs (SAANDs). Of special note are presentations on the companys second-generation compound, CP461, including data showing that oral CP461 increased survival in a rat model of human lung cancer equivalent to that produced by injected Taxotere (docetaxel), the currently approved chemotherapeutic for advanced non-small cell lung cancer (NSCLC). New data being presented shows that CP461 exhibits anti-proliferative, as well as pro-apoptotic effects on tumor cells in culture and in animal models, and that the drug is selective for tumor cells over normal cells.

An ideal anti-cancer agent would halt the uncontrolled growth or proliferation of abnormal cells while at the same time selectively promoting apoptosis or programmed cell death, said Rifat Pamukcu, M.D., chief scientific officer of Cell Pathways, Inc. This research demonstrates that CP461 acts against cancer cells selectively through both those mechanisms in unison, not only in cancer cells grown in the laboratory but also in a relevant animal model of human NSCLC. Moreover, this compound prevents new blood vessel formation (anti-angiogenic activity) in preclinical models even in the presence of growth stimulators like VEGF. Preventing such new blood vessel formation is also an anti-proliferative effect with potential utility in cancer treatment.

Cell Pathways is currently conducting Phase I/II clinical investigations with CP461 as a single-agent in a variety of cancer indications. Ongoing studies include clinical trials in chronic lymphocytic leukemia, hormone-refractory prostate cancer and advanced kidney cancer.

Potential Single-Agent Activi
'"/>

Contact: Joan Kureczka
Jkureczka@aol.com
415-821-2413
Kureczka/Martin Associates
8-Apr-2002

Page: 1 2 3 4
Related biology news :

1. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
2. Pathways of emotion from cortex to peripheral organs
3. Cell Pathways scientists describe mechanism by which SAANDS compounds trigger programmed death in cancerous and precancerous cells
4. Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps
5. Pitt Researchers Find Way To Block Cellular Growth Pathways And Inhibit Tumor Growth
6. Discovery Of Genetic Pathways May Provide New Ways To Combat Candida Infections
7. New genetic research demonstrates possible cause of inherited form of Parkinsons disease
8. Study demonstrates altered angiogenic proteins in preeclampsia patients
9. New study demonstrates bone protein can reverse kidney failure
10. Study demonstrates that low dose tamoxifen may be effective in treating breast cancer
11. Animal study demonstrates carbon monoxide may help heart patients